The Italian Society of Infectious and Tropical Diseases (SIMIT) of the Technical Health Committee, Ministry of Health (Sections L and M) of Italy have supported recommendations for the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. This publication summarizes the latest updates to the 2016 version of the Italian Guidelines for the management of HIV-1 infected patients and the use of antiretroviral drugs. In particular, new recommendations were released concerning the following topics: estimate of the HIV continuum of care in Italy, optimal timing and preferred drug combinations for starting antiretroviral therapy, treatment optimization, and pre-exposure prophilaxis (PrEP). For a complete review of clinical and therapeutic relevant topics we refer the reader to the extended version of the Guidelines.
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons : update 2016 / A. Antinori, A. Di Biagio, S. Marcotullio, M. Andreoni, A. Chirianni, A. d'Arminio Monforte, M. Galli, F. Mazzotta, C. Mussini, M. Puoti, A. Lazzarin. - In: NEW MICROBIOLOGICA. - ISSN 1121-7138. - 40:2(2017 Apr), pp. 86-98.
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons : update 2016
A. d'Arminio Monforte;M. Galli;A. Lazzarin
2017
Abstract
The Italian Society of Infectious and Tropical Diseases (SIMIT) of the Technical Health Committee, Ministry of Health (Sections L and M) of Italy have supported recommendations for the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. This publication summarizes the latest updates to the 2016 version of the Italian Guidelines for the management of HIV-1 infected patients and the use of antiretroviral drugs. In particular, new recommendations were released concerning the following topics: estimate of the HIV continuum of care in Italy, optimal timing and preferred drug combinations for starting antiretroviral therapy, treatment optimization, and pre-exposure prophilaxis (PrEP). For a complete review of clinical and therapeutic relevant topics we refer the reader to the extended version of the Guidelines.File | Dimensione | Formato | |
---|---|---|---|
86.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
496.68 kB
Formato
Adobe PDF
|
496.68 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.